For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Thymosin alpha-1
Illustration for Thymosin alpha-1

THE PEPSRADAR ENCYCLOPEDIA

Thymosin alpha-1

Immune modulation

Research topics · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Thymosin alpha-1 · KEY FACTS

Content updated · how dates work

Saved peptides

Compare: Thymosin alpha-1 vs Thymosin beta-4

What is Thymosin alpha-1?

Thymosin alpha-1, also called thymalfasin, is investigated for immune-related effects. The clinical value of immune modulation depends on the disease and endpoint.

Video overview · 3:35

Thymosin Alpha-1: Does It Really Boost Immunity and Prevent Infections? What the Trials Show

Where thymosin alpha-1 is approved, why immune markers are not the same as fewer infections, what the large sepsis and pancreatitis trials found, the hepatitis and COVID-19 evidence, and its FDA and anti-doping status.

Narrated with an AI voice from this profile's sources; education only, no dosing.

Read the transcript

Thymosin alpha-1 is a peptide sold online as an immune booster that helps prevent infections. Unlike most research peptides, it is an approved drug in dozens of countries, though not in the US. But when the biggest trials tested whether it prevents infections or saves lives, the answer was no. Here is what the evidence shows.

Thymosin alpha-1 helps activate and regulate several kinds of immune cells. Its lab-made form, thymalfasin, is sold as Zadaxin. Its maker reported approvals in more than thirty countries, under a license covering regions outside the US and Europe. It is not FDA approved.

Here is the key distinction. Thymosin alpha-1 often moves immune markers in the expected direction, like T-cell counts and a monocyte marker called HLA-DR. But a better lab marker is not the same as fewer infections or fewer deaths, and that is what the large trials tested.

Sepsis is the clearest test. A 2013 trial of three hundred sixty-one patients reported fewer deaths, twenty-six versus thirty-five percent, but it was single-blind and the result was borderline. Then a much larger double-blind trial, TESTS, enrolled eleven hundred and six adults. Deaths at twenty-eight days were twenty-three point four percent with the drug and twenty-four point one percent with placebo: no difference.

The most direct test of infection prevention is the TRACE trial. Five hundred eight patients with severe pancreatitis, where dead tissue often becomes infected, got thymosin alpha-1 or placebo. Infections developed in fifteen point seven percent versus eighteen point one percent, a difference that was not statistically significant. Vaccine studies are more positive, but small: they showed higher antibody levels, not fewer infections.

In hepatitis B, a 2026 Cochrane review of ten trials said it may reduce deaths, but rated the evidence low to very low certainty. In hepatitis C, a trial of five hundred fifty-two patients found similar cure rates with or without it. And in COVID-19, a meta-analysis of more than five thousand patients found no significant effect on deaths.

Thymosin alpha-1 is not FDA approved. In trials it was generally well tolerated, mainly with injection-site irritation, and the big sepsis trial found no safety differences from placebo. But the FDA has flagged possible immune reactions, impurities and inadequate safety information for compounded versions. Its anti-doping status is unclear, because it is approved in other countries.

Does thymosin alpha-1 boost the immune system? Partly: it shifts immune markers in trials. Does it prevent infections? Not shown: the largest trial of that was negative. Does it save lives in sepsis? The biggest double-blind trial found no difference. And is it approved? In other countries, yes, but not in the US. PepsRadar's claim check rates the claim partly supported.

The bottom line: thymosin alpha-1 is a real drug, approved in other countries, and it can move immune markers. But the largest, best-designed trials did not show fewer infections or deaths, and it is not FDA approved. For every study and source, see the thymosin alpha-1 profile on PepsRadar dot com.

Biological role or research focus

Immune modulation.

Findings in severely ill patients must not be generalized to “boosting immunity” in healthy people.

Role reference: The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. ↗

Names you may encounter

thymosin alpha 1 · TA-1 · thymalfasin

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Immunomodulatory peptide
Main research area
Disease-specific immune research
Evidence featured
Human phase 3 trial
Source check
October 4, 2026

Source: The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. ↗

Quick answers

Is Thymosin alpha-1 FDA approved?
No. No FDA-approved drug contains Thymosin alpha-1. Source ↗
Is Thymosin alpha-1 safe?
Approved in many countries outside the US but not FDA-approved. Trials report good tolerability, mainly injection-site irritation; FDA calls compounded-product safety information inadequate. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
Is Thymosin alpha-1 banned in sport?
It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
Has the FDA taken action over Thymosin alpha-1?
Yes. Our records list 1 FDA action naming it, most recently on November 10, 2021: FDA warning letter to a clinic-based compounder (Guyer Institute) stating thymosin alpha had not been nominated for the 503A bulks list and could not be used under the 503A exemptions. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Human research
StudyTypePopulation / model
TESTS (2025)Human phase 3 trial1,106 adults with sepsis randomized across 22 centers in China.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human phase 3 trial · 2025

TESTS

The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.

Population / model
1,106 adults with sepsis randomized across 22 centers in China.
Study design
Blinded placebo-controlled trial; 1,089 participants in the modified intention-to-treat analysis.
Main finding
Twenty-eight-day mortality was 23.4% versus 24.1%; hazard ratio 0.99 (95% CI 0.77–1.27). No clear mortality benefit was demonstrated.
Limits & context
A large negative overall result should not be replaced by favorable subgroup headlines. Sepsis treatment also differs substantially from immune-enhancement claims in healthy people.

Source: The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

43 registered studies name Thymosin alpha-1 as an intervention; 10 are recruiting or under way, 4 have not started recruiting yet, 14 completed and 15 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
Thymosin Alpha 1 and IgM Levels in Sepsis
NCT07922954 · Southeast University, China
Active, not recruitingPhase 42026-02-2036
Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment
NCT07884201 · Fudan University
Not yet recruitingPhase 22026-11-08572
Thymalfasin for Immune Recovery in Adults With Sepsis
NCT07866118 · Shanghai Zhongshan Hospital
RecruitingNot applicable2026-10-0660
Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer
NCT07780721 · The Affiliated Hospital of Putian University
Not yet recruitingPhase 22026-08-3031
Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine
NCT06821100 · The Methodist Hospital Research Institute
RecruitingPhase 12024-12-0275
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer
NCT06024356 · Beijing Friendship Hospital
Completed2023-09-2047
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma
NCT07644897 · Sun Yat-sen University
RecruitingPhase 22023-05-3055
Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients
NCT04428008 · William B. Ershler, MD
CompletedPhase 22021-01-12189

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 43 listed studies.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Thymosin alpha-1. ↗
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2001 May 15 · Journal Article, Review

Aging and Thymosin Alpha-1. ↗
International journal of molecular sciences · 2025 Nov 27 · Journal Article, Review
Read available full text ↗

beta-Thymosins. ↗
Annals of the New York Academy of Sciences · 2007 Sep · Journal Article, Research Support, Non-U.S. Gov't, Review

Thymosin alpha-1 treatment in chronic hepatitis B. ↗
Expert opinion on biological therapy · 2015 · Editorial, Research Support, Non-U.S. Gov't

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Approved in many countries outside the US but not FDA-approved. Trials report good tolerability, mainly injection-site irritation; FDA calls compounded-product safety information inadequate.

Human safety data: Very limited

Approved outside the US (in over 35 countries, per a 2009 review) for hepatitis and immune uses, but not by FDA. A large sepsis trial found no safety differences from placebo; a Cochrane review rated adverse-event evidence low to very low certainty.

Unassessed: little human safety data

It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Serious risks

  • Possible immune reactions (immunogenicity) and impurities in compounded products, per FDA's compounding safety listing

Side effects reported in studies

  • injection-site irritation

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: TESTS: thymosin alpha 1 for sepsis, phase 3 trial (BMJ, 2025) ↗ · Thymosin alpha-1 (review, Am J Health Syst Pharm, 2001) ↗ · Emerging clinical applications of thymosin alpha 1 (2009) ↗ · Thymosin alpha 1 for chronic hepatitis B (Cochrane review, 2026) ↗ · FDA: Bulk drug substances that may present significant safety risks ↗

Safety evidence & remaining uncertainty

FDA considers compounded-product safety information inadequate. Trial tolerability in critically ill patients does not establish suitability for routine wellness use.

Source: FDA · Peptide compounding safety concerns ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Formerly Category 2 (FDA flagged safety risks); nominations withdrawn
Was in 503A category 2 (significant safety risks) as "Thymosin-alpha 1 (Ta1)". The nominations were withdrawn by the nominators and FDA moved it to the "nominated but withdrawn" table (page updated April 22, 2026). It is not in category 1 and is not on the 503A bulks list. source
World Anti-Doping Agency (2026)
Not on the WADA Prohibited List
Not named. S0 only applies to substances with no government approval anywhere; thymalfasin (thymosin alpha-1) is reported to be approved in a number of countries outside the US (not verified here), so whether S0 applies is uncertain. Athletes should check with their anti-doping organization. source

FDA actions

  • FDA warning letter to a clinic-based compounder (Guyer Institute) stating thymosin alpha had not been nominated for the 503A bulks list and could not be used under the 503A exemptions. (2021-11-10) source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Research context & status

The selected phase 3 sepsis trial did not demonstrate a mortality benefit. It should not be used as support for an undefined “immune boost” in healthy people.

Source: The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Seller lab-report checks and prices are available to members. Sign up free

Mechanism & research rationale

Research aims to alter immune responses rather than simply increase them. A meaningful test asks whether that intervention improves a patient outcome such as survival.

Source: The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. ↗

Molecular structure

Thymosin alpha-1: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 16130571 ↗

Questions worth asking

  • What specific product, route, and research population does the claim refer to?
  • Does the source measure an outcome in people, or only a laboratory marker?
  • Findings in severely ill patients must not be generalized to “boosting immunity” in healthy people.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Video & podcast discussions: members library

Frequently asked questions

Did TESTS demonstrate lower 28-day mortality?

No clear reduction was found in the overall analysis.

Source: The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. ↗

Does an immune mechanism guarantee clinical benefit?

No. Altering a pathway and improving health are separate questions, and immune effects can depend on context.

Source: The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Thymosin alpha-1

Download illustration ↓Source record ↗
Thymosin alpha-1 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.